RESEARCH NEWS: Another clinical trial for Duchenne Muscular Dystrophy has started. Dutch biopharmaceutical company Prosensa has announced the initiation of another exon skipping clinical trial for Duchenne muscular dystrophy (DMD). The potential drug being tested is called ‘PRO053’ and is a ‘molecular patch’ designed skip a portion of the dystrophin gene called ‘exon 53’. It has the potential to treat around eight percent of boys with DMD. The first patient in the trial has now had his first injection of PRO053. This phase 1/2 clinical trial is designed to assess the safety, effectiveness and tolerability of multiple doses of PRO053 over 48 weeks. They will also study how PRO053 moves through the body for example the rate at which it is absorbed and excreted – this is called the ‘pharmacokinetics’... [continues] To read the full update please click the the link below to download the current edition of Research News: mda.org.au/Media/Releases/Research_News_10_Sept_2013.pdf
Posted on: Tue, 10 Sep 2013 01:51:14 +0000
Trending Topics
Recently Viewed Topics
© 2015